Pulmonx to Participate at Upcoming Investor Conferences

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences.

Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT / 2:25pm ET. Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

Pulmonx management will also be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 16, 2023.

About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Investor ContactBrian JohnstonGilmartin [e-mail]